Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C

Bibliography

• Metts J, Carmichael L, Kokor W, et al. Hepatitis C: prevalence, transmission, screening, and prevention. FP Essent 2014;427:11–17
   PubMedGoogle Scholar
• Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012;157(11):817–22
   PubMed Web of Science ®Google Scholar
• Ferenci P. Treatment of chronic hepatitis C – are interferons really necessary? Liver Int 2012;32:108–12
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the Ion-1, 2 and 3 clinical trials. Hepatology 2015;61(6):1798–808
   PubMed Web of Science ®Google Scholar
• McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008;15:475–81
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–72
   PubMed Web of Science ®Google Scholar
• Marcellin P, Roberts SK, Reddy KR, et al. Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf 2012;11:901–9
   PubMed Web of Science ®Google Scholar
• Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450–5.e2
   PubMed Web of Science ®Google Scholar
• Rose L, Bias TE, Mathias CB, et al. Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection. Ann Pharmacother 2014;48(8):1019–29
   PubMed Web of Science ®Google Scholar
• Herbst DA, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013;22:527–36
   PubMed Web of Science ®Google Scholar
• Belema M, Lopez OD, Bender JA, et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J Med Chem 2014;57:1643–72
   PubMed Web of Science ®Google Scholar
• Link JO, Taylor JG, Xu L, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014;57:2033–46
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013;59:375–82
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Gruener D, Hill JM, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012;57:24–31
   PubMed Web of Science ®Google Scholar
• German P, Mathias A, Pang PS, et al. Lack of a clinically significant pharmacokinetic drug-drug interaction between Sofosbuvir (GS-7977) and GS-5885 or GS-9669 in healthy volunteers. Hepatology 2012;56:1072A–3A
   Web of Science ®Google Scholar
• Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol 2015;11(3):1–9
   Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2015;370:1889–98
   Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and Sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–88
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–93
   PubMed Web of Science ®Google Scholar
• Gilead. Gilead Sciences Inc. (2015). Harvoni (prescribing information); Foster City, California: 2015
   Google Scholar
• Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15(6):645–53
   Google Scholar
• Gilead. Serious and life threatening cases of symptomatic Bradycardia as well as one case of fatal cardiac arrest reported with coadministration of Amiodarone with either harvoni (ledipasvir and sofosbuvir fixed-dose combination) or with Sovaldi in combination with another direct acting antiviral. 2015
   Google Scholar
• Flamm SL GTE, Charlton M, Denning JM, et al. LDV/SOF with Ribavirin for the treatment of HCV in patients with decompansated cirrhosis: preliminary results of a prospective, multicenter study.(SOLAR-1, Cohort A). Hepatology 2014;60:320A
   Google Scholar
• Reddy KR, Everson GT, Steven L, et al. Ledipasvir/Sofosbuvir with Ribavirin for the treatment of HCV in patients with post transplant recurence: preliminary results of a prospective, multicenter study (SOLAR-1, Cohort B). Hepatology 2014
   Google Scholar
• Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15(4):397–404
   PubMed Web of Science ®Google Scholar
• Osinusi A, Kohli A, Marti MM, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med 2014;161:634–8
   PubMed Web of Science ®Google Scholar
• Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313:1232–9
   PubMed Web of Science ®Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir/Sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1. The Conference of Retroviruses and Opportunistic Infections; 23 – 26 February 2015; Seattle, WA
   Google Scholar
• Gane EJ, Robson RA, Bonacini M, et al. Safety, antiviral efficacy, and pharmacokinetics of Sofosbuvir in patients with severe renal impairment. Hepatology 2014;60:133A
   Google Scholar
• Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014;46(Suppl 5):S186–96
   PubMedGoogle Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756–65
   PubMed Web of Science ®Google Scholar
• Jody Gilmore KL, Breen D, Trooskin S, et al. Effectiveness of Sofosbuvir/Simeprevir for HIV/HCV patients in clinical practice. The Conference of Retroviruses and Opportunistic Infections; 23 – 26 February 2015; Seattle, WA
   Google Scholar
• Marks KM, Weinberg EM, Kumar S, et al. Sofosbuvir, Simeprevir, +/- Ribavirin in HCV G1 protease inhibitor experienced patients. The Conference of Retroviruses and Opportunistic Infections; 23 – 26 February 2015; Seattle, WA
   Google Scholar
• Bichoupan K, Tandon N, Yalamanchili R, et al. Branch. Real world cost per SVR with Simeprevir/Sofosbuvir ± Ribavirin. The Conference of Retroviruses and Opportunistic Infections; 23 – 26 February 2015; Seattle, WA
   Google Scholar
• Available from: www.hcvguidelines.org
   Google Scholar